| Literature DB >> 27695324 |
Rosana Simón-Vázquez1, Tamara Lozano-Fernández1, Angela Dávila-Grana1, Africa González-Fernández1.
Abstract
Besides cell death, nanoparticles (Nps) can induce other cellular responses such as inflammation. The potential immune response mediated by the exposure of human lymphoid cells to metal oxide Nps (moNps) was characterized using four different moNps (CeO2, TiO2, Al2O3, and ZnO) to study the three most relevant mitogen-activated protein kinase subfamilies and the nuclear factor kappa-light-chain-enhancer of the activated B-cell inhibitor, IκBα, as well as the expression of several genes by immune cells incubated with these Nps. The moNps activated different signaling pathways and altered the gene expression in human lymphocyte cells. The ZnO Nps were the most active and the release of Zn2+ ions was the main mechanism of toxicity. CeO2 Nps induced the smallest changes in gene expression and in the IκBα protein. The effects of the particles were strongly dependent on the type and concentration of the Nps and on the cell activation status prior to Np exposure.Entities:
Keywords: Jurkat; MAPK; NFκB; inflammation; metabolism; qPCR
Mesh:
Substances:
Year: 2016 PMID: 27695324 PMCID: PMC5028082 DOI: 10.2147/IJN.S110465
Source DB: PubMed Journal: Int J Nanomedicine ISSN: 1176-9114
Figure 1Expression of p-ERK (1,2), p-p38, p-SAPK/JNK, and IκBα in Jurkat cells incubated with CeO2, TiO2, Al2O3, and ZnO Nps.
Notes: The cells were tested in the presence (+PHA) or absence (−PHA) of PHA to assess the effect of lymphocyte preactivation on the cell response to the Nps. GAPDH was used as a loading control and two different times were tested (1 and 3 hours). The protein was quantified and the difference in the protein levels is shown. The bars represent the average intensity normalized to the control sample and the error bars represent the standard deviation. *Statistically significant difference (P<0.05) in the level of protein compared with the control (sample without Nps). The horizontal lines represent the treated samples that are statistically different from the control sample for both proteins studied. All Nps were tested at 100 μg/mL, except for ZnO (50 μg/mL).
Abbreviations: ERK, extracellular signal-regulated kinase; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; h, hour; IκBα, nuclear factor kappa-light-chain-enhancer of the activated B-cell inhibitor; JNK, c-Jun amino-terminal kinase; Nps, nanoparticles; PHA, phytohemagglutinin; SAPK, stress-activated protein kinase.
Figure 2Influence of the Zn2+ ion concentration on the activation of MAPK and NFκB in Jurkat cells.
Notes: The influence of ion release on the toxicity induced by ZnO nanoparticles was studied by incubating Jurkat cells, prestimulated (+PHA) or not (−PHA) with PHA, with three different concentrations of ZnCl2 salt as the source of Zn2+ ions (1, 10, and 100 μg/mL), and measuring the activation of ERK (1,2), p38, SAPK/JNK, and the NFκB pathways at 1 and 3 hours. *Statistically significant difference (P<0.05) in the level of protein compared with the control (untreated sample). The horizontal lines represent the treated samples that are statistically different from the control sample for both proteins studied.
Abbreviations: ERK, extracellular signal-regulated kinase; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; IκBα, NFκB inhibitor; JNK, c-Jun amino-terminal kinase; MAPK, mitogen-activated protein kinase; NFκB, nuclear factor kappa-light-chain-enhancer of the activated B-cell; PHA, phytohemagglutinin; SAPK, stress-activated protein kinase.
Changes in the expression of selected genes in the Jurkat cell line
| CeO2 | TiO2 | Al2O3 | ZnO | Gene | Name | Function |
|---|---|---|---|---|---|---|
| 3.17 | 0.84 | Beta-actin | Cell structure and motility | |||
| 0.76 | 2.24 | Beta-2-microglobulin | Component of the MHC class I | |||
| 1.55 | 3.84 | BCL2-associated X protein | Apoptotic activator | |||
| 1.77 | BCL2-related protein A1 | Anti-apoptotic | ||||
| 0.95 | 0.94 | 2.69 | 1.33 | Baculoviral IAP repeat-containing 2 | Apoptotic inhibitor | |
| 0.70 | 3.58 | 1.23 | Baculoviral IAP repeat-containing 3 | Apoptotic inhibitor | ||
| 1.37 | 1.11 | Chemokine (C–C motif) ligand 2 | Chemotactic factor | |||
| 0.70 | 0.80 | Cyclin D1 | Cell cycle regulation | |||
| 2.44 | 2.51 | 2.73 | 3.79 | Cyclin-dependent kinase inhibitor 1A | Cell cycle G1 phase arrest | |
| 3.21 | 0.71 | Cyclin-dependent kinase inhibitor 1B | Cell cycle progression at G1 | |||
| 1.14 | 3.33 | 0.85 | CCAAT/enhancer-binding protein beta | Transcription factor | ||
| 0.99 | Cytochrome P450, family 19-A, 1 | Drug metabolism | ||||
| 1.44 | Fatty acid synthase | Lipid metabolism | ||||
| 1.36 | 3.31 | 0.77 | Growth arrest and DNA-damage-inducible, alpha | Cell cycle arrest, DNA repair | ||
| 0.72 | 0.88 | 0.97 | 0.41 | Glycogen synthase 1 | Glycogen metabolism | |
| 1.17 | 1.21 | 2.44 | 1.02 | Inhibitor of κ light polypeptide gene enhancer in B cells, kinase beta | NF-kappa-B signaling pathway | |
| 1.29 | 0.73 | 3.51 | Interleukin-2 | T-cell clonal expansion. Th1 | ||
| 3.41 | Interleukin-8 | Chemokine | ||||
| 0.83 | 1.32 | 2.27 | Jun proto-oncogene | Transcription factor | ||
| 1.82 | 2.05 | p53 E3 ubiquitin protein ligase homologue | Inhibitor of p53 | |||
| NLR family, apoptosis inhibitory protein | Apoptotic inhibitor | |||||
| 0.83 | 3.05 | Peroxisome proliferator-activated receptor gamma | Nuclear receptor/glucose homeostasis | |||
| 0.72 | 0.90 | 1.38 | 0.38 | Protein kinase C, epsilon | Cell adhesion/cell cycle | |
| 1.01 | 1.42 | 3.73 | 0.50 | Patched 1 | Receptor/tumor suppressor | |
| 2.56 | Retinol-binding protein 1, cellular | Carrier protein/retinol transport | ||||
| 0.59 | 1.56 | 1.64 | 0.39 | Vascular endothelial growth factor A | Growth factor |
Notes: Jurkat cells were incubated for 24 hours with CeO2, TiO2, Al2O3, and ZnO Nps. The values in the table represent the relative quantification with respect to the control sample (in the absence of Nps). The genes upregulated or downregulated (at least fourfold or more) are highlighted in bold.
Abbreviations: NF, nuclear factor; Nps, nanoparticles; NLR, NOD-like receptors.